Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IRD | 8-K | neutral | 5/10 | Opus Genetics reported Q2 2026 results with a net loss of $8.1M ($0.08 basic EPS) vs $7.4M loss a year ago, while revenu | Aug 6, 2026 |
| PBH | PRESS-RELEASE | bullish | 6/10 | Prestige Consumer Healthcare reported Q1 FY2027 revenue of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98 (+3.2% | Aug 6, 2026 |
| TEVA | CLUSTER | neutral | 2/10 | Two Teva insiders (Hughes and Jover) sold a combined $1.34M in open-market shares on August 3, 2026, at ~$34.88/share, f | Aug 6, 2026 |
| ALMS | CLUSTER | neutral | 2/10 | Six C-suite insiders at Alumis Inc. (ALMS) collectively sold $394K worth of shares on August 3, 2026, all at $26.37 per | Aug 6, 2026 |
| VCEL | CLUSTER | neutral | 2/10 | Two Vericel insiders sold a combined $541,400 in shares over a 7-day window, with the COO's sale being a same-day exerci | Aug 6, 2026 |
| MAZE | CLUSTER | neutral | 3/10 | CEO Jason Coloma and CSBO Atul Dandekar sold a combined $1.0M in MAZE shares over a 7-day window, with the CEO alone sel | Aug 6, 2026 |
| CAMP | CLUSTER | bullish | 8/10 | A powerful insider buying cluster at Camp4 Therapeutics: 5AM Partners VI (a 10% owner) made a $4.86M open-market purchas | Aug 6, 2026 |
| TWST | CLUSTER | neutral | 2/10 | Five Twist Bioscience insiders, including CEO Emily Leproust and President/COO Patrick Finn, sold a combined $884K in op | Aug 6, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Three C-suite insiders at Castle Biosciences (CEO, COO, CCO) sold a total of ~$293K in open-market shares over a 7-day w | Aug 6, 2026 |
| FATE | CLUSTER | bearish | 5/10 | Two insiders at Fate Therapeutics, including the CEO, sold a combined $204K worth of shares in open-market transactions | Aug 6, 2026 |
| PCVX | CLUSTER | neutral | 2/10 | Two top executives at Vaxcyte, the CEO and CFO, sold a combined $395K in open-market stock over a one-week window, with | Aug 6, 2026 |
| PFE | CLUSTER | neutral | 3/10 | Two Pfizer directors, Ronald Blaylock and Mortimer Buckley, made open-market purchases totaling ~$1.96M on August 5, 202 | Aug 6, 2026 |
| AMGN | GOVT-CONTRACT | neutral | 3/10 | Amgen USA Inc received a $66M modification to an existing HHS contract, exercising Option Period 4A. The award is a rout | Aug 6, 2026 |
| APGE | INST-CLUSTER | mixed | 5/10 | Apogee Therapeutics (APGE) saw a mixed institutional cluster in Q2 2026: 4 buyers added $42.8M in new holdings (led by C | Aug 6, 2026 |
| ALLO | INST-CLUSTER | bullish | 5/10 | 7 institutional buyers accumulated $7.9M in ALLO during 2026-Q2, led by Aberdeen Group doubling its stake to $10.4M and | Aug 6, 2026 |
| AGIO | INST-CLUSTER | mixed | 4/10 | In Q2 2026, four institutional buyers accumulated $4.9M in AGIO while two sellers trimmed $1.2M, resulting in a net mixe | Aug 6, 2026 |
| ABVX | INST-CLUSTER | mixed | 5/10 | Four institutional investors doubled their ABVX positions in Q2 2026, led by Pictet Asset Management ($54.4M increase) a | Aug 6, 2026 |
| XNCR | 8-K | bullish | 7/10 | Xencor reported Q2 2026 revenue of $51.2M (vs $18.9M consensus) and EPS of -$0.29 (vs -$0.84 consensus), a significant b | Aug 5, 2026 |
| MIRM | 8-K | mixed | 6/10 | Mirum Pharmaceuticals reported Q2 2026 net product sales of $176.2M, a 38% YoY increase, and raised full-year guidance t | Aug 5, 2026 |
| KMDA | 6-K | neutral | 2/10 | Kamada Ltd. held its Annual General Meeting on August 5, 2026, and shareholders approved all proposals, including re-ele | Aug 5, 2026 |
| ATTO | 424B4 | bullish | 6/10 | Attovia Therapeutics priced its 17M-share IPO at $17.00/share, raising ~$289M in gross proceeds ($265.1M net). The clini | Aug 5, 2026 |
| BDTX | 8-K | neutral | 5/10 | Black Diamond Therapeutics reported Q2 2026 results with a net loss of -$0.17 per share, slightly narrower than the -$0. | Aug 5, 2026 |
| SYRE | CLUSTER | bearish | 5/10 | CEO Turtle Cameron and CFO Scott Burrows sold a combined $561K in open-market sales on August 3, 2026, with the CEO sell | Aug 5, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Three Arcutis insiders (Watanabe, Matsuda, Burnett) sold a total of $171K in open-market sales on August 3, 2026, at ~$2 | Aug 5, 2026 |
| VREOF | 8-K | bullish | 7/10 | Vireo Growth Inc. (VREOF) has entered into two separate Securities Purchase Agreements to acquire all of the membership | Aug 5, 2026 |
| ABBV | 8-K | neutral | 4/10 | AbbVie entered into an underwriting agreement to issue and sell $10.0 billion aggregate principal amount of senior notes | Aug 5, 2026 |
| ALMS | CLUSTER | neutral | 4/10 | Five C-suite insiders at Alumis (ALMS) sold a combined $326K in open-market sales on August 3, 2026, all at $26.37. The | Aug 5, 2026 |
| TARS | PRESS-RELEASE | neutral | 1/10 | Tarsus Pharmaceuticals, Inc announced it will report its Q2 2026 results on August 6, 2026. | Aug 5, 2026 |
| LLY | COURT-RULING | bullish | 5/10 | Eli Lilly's lawsuit against Revive RX for unauthorized compounding of tirzepatide (Mounjaro/Zepbound) survives a motion | Aug 5, 2026 |
| NVS | COURT-RULING | neutral | 2/10 | A federal magistrate judge denied without prejudice Novartis's generic-drug defendants' motion to compel discovery into | Aug 5, 2026 |